References
- Bergstrom R. F., Van Lier R. B. L., Lemberger L., Tenbarge J. L. Absolute bioavailability of fluoxetine in beagle dogs. Abstracts of the American Pharmaceutical Association Academy of Pharmaceutical Sciences 1986; 16: 125
- Caccia S., Cappi M., Fracasso C., Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology 1990; 100: 509–524
- Fabre L. F., Putman H. P. An ascending single-dose tolerance study of Wy-45,030, a bicyclic antidepressant, in healthy men. Current Therapeutic Research 1987; 42: 901–909
- Fuller R. W., Snoddy H. D., Perry K. W., Bymaster F. P., Wong D. T. Importance of duration of drug action in the antagonism of p-chloroamphetamine depletion of brain serotonin. Comparison of fluoxetine and chlorimipramine. Biochemical Pharmacology 1978; 27: 193–198
- Gibaldi M., Perrier D. Pharmacokinetics2nd Edn. Marcel Dekker, New York 1982
- Goldberg H. L., Finnerty R. An open-label variable-dose study of Wy-45,030 (Venlafaxine) in depressed outpatients. Psychopharmacology Bulletin 1988; 24: 198–199
- Hicks D. R., Wolaniuk D., Russell A., Cavanaugh N., Kraml M. A high-performance liquid chromatographic method for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in plasma. Therapy and Drug Monitoring 1994; 16: 100–107
- Horng J. S., Wong D. T. Effects of serotonin uptake inhibitor, Lilly 110140, on transport of serotonin in rats and human blood platelets. Biochemical Pharmacology 1976; 25: 865–867
- Howell S. R., Husbands G. E. M., Scatina J. A., Sisenwine S. F. The metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and human. Xenobiotica 1993; 23: 349–359
- Husbands G. E. M., Yardley J. P., Muth E. A. US Patent No. 4,535,186, 1985, 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
- Kelly M. W., Perry P. J., Holstad S. G., Garvey M. J. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Therapy and Drug Monitoring 1989; 11: 165–170
- Klamerus K. J., Maloney K., Rudolph R. L., Sisenwine S. F., Jusko W. J., Chiang S. T. Introduction of a composite parameter to the pharmacokinetic of venlafaxine and its active O-desmethyl metabolite. Journal of Clinical Pharmacology 1992; 32: 716–724
- Mitchell P. J., Fletcher A., Redfern P. H. Is antidepressant efficacy revealed by drug-induced changes in rat behavior exhibited during social interaction?. Neuroscience and Biobehavioral Reviews 1991; 15: 539–544
- Montgomery S. A. Venlafaxine: a new dimension in antidepressant pharmacotherapy. Journal of Clinical Psychiatry 1993; 54: 1–8
- Moyer J. A., Muth E. A., Haskins J. T., Lappe R. W., Sigg E. B. In vivo antidepressant profiles of the novel bicyclic compounds Wy-45,030 and Wy-45,881. Society for Neuroscience 1984; 10: 261
- Muth E. A., Haskins J. T., Moyer J. A., Husbands G. E. M., Nielsen S. T., Sigg E. B. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, and ethyl cyclo-hexanol derivative. Biochemical Pharmacology 1986; 35: 4493–4497
- Muth E. A., Moyer J. A., Haskins J. T., Andree T. H., Husbands G. E. Biochemical, neurophysiological and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Development Research. 1993, in press
- Schweizer E., Clary C., Weise C., Rickels K. An open-label, dose-finding study of Wy-45,030, a novel bicyclic antidepressant. Psychopharmacology Bulletin 1988; 24: 195–197
- Wang C. P., Howell S. R., Scatina J. A., Sisenwine S. F. The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine. Chirality 1992; 4: 84–90
- Yardley J. P., Husbands G. E. M., Stack G., Butch J., Bicksler J., Moyer J. A., Muth E. A., Andree T., Fletcher H., James M. N. G., Sielecki A. R. 2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives; synthesis and antidepressant activity. Journal of Medical Chemistry 1990; 33: 2899–2905